Specialty pharmacy costs continue to rise at a pace that challenges self-funded employers nationwide. For many health plans, specialty drugs now represent the largest and fastest-growing portion of total pharmacy spend.
As employers look for solutions to control specialty drug costs, alternative funding programs such as Manufacturer Assistance Programs(MAPs), Patient Assistance Programs (PAPs), and Copay Assistance Programs(CAPs) are gaining attention.
Through our partnership with Navion, BRMS has been evaluating how these programs can support smarter pharmacy cost management. Navion provides deep pharmacy expertise, and as a nationwide third-party administrator, BRMS evaluates these strategies within the full context of the employer’s benefit plan.
These programs can deliver savings, but they are not plug-and-play solutions. Employers need more than a basic definition. They need clarity on:
- Member eligibility requirements
- Impact on pharmacy rebates
- Administrative and operational complexity
- Potential disruption to members
- Alignment with PBM contracts
A strategic TPA does not simply implement cost-saving programs. It evaluates how they fit within the broader plan strategy.
What Are Manufacturer Assistance Programs and Patient Assistance Programs?
Manufacturer Assistance Programs (MAPs) and Patient Assistance Programs (PAPs) are manufacturer-funded initiatives designed primarily to support uninsured or income-eligible individuals who need high-cost medications.
In a self-funded health plan environment, MAPs and PAPs are often used as part of an alternative funding strategy when specialty drugs are carved out or when a third-party vendor coordinates access.
How MAP and PAP Programs Work
- The drug manufacturer provides medication at reduced or no cost for eligible individuals
- Eligibility is typically income-based and requires documentation
- Third-party vendors often manage enrollment and compliance
- Savings are generated when members qualify and access manufacturer support instead of plan-funded benefits
While these programs can reduce employer pharmacy spend, eligibility limitations can restrict participation. Administrative coordination is also required, which adds complexity to plan operations.
MAP and PAP programs can be effective when member demographics and utilization patterns support eligibility. They may not generate meaningful savings if qualification rates are low or if rebate loss outweighs funding gains.
What Is a Copay Assistance Program?
A Copay Assistance Program (CAP) involves manufacturer-funded copay cards that reduce member out-of-pocket costs for brand-name medications.
CAP strategies are frequently paired with accumulator or maximizer programs within pharmacy benefit designs.
How CAP Programs Affect Employers
- Members experience lower out-of-pocket costs at the pharmacy counter
- The plan may capture savings through structured benefit design
- CAP strategies typically integrate with existing PBM structures, but benefit design elements (such as accumulators or maximizers) should be evaluated for alignment
• Member communication should focus on how copay assistance interacts with plan design, particularly when accumulators or maximizers are in place
Copay assistance programs can support both affordability and plan savings when aligned with overall benefit design.
Clear structuring, particularly around accumulators or maximizers, helps ensure the program delivers intended savings while maintaining a predictable member experience.
When Do MAP, PAP, and CAP Programs Work Best?
Alternative funding programs can reduce specialty drug costs, but only under the right conditions.
Before recommending implementation, BRMS evaluates:
- Specialty drug utilization trends
- Member income eligibility likelihood
- Existing rebate structures for high-cost medications
- PBM contract flexibility and alignment
- Member experience and medication adherence risks
Savings projections must account for net financial impact, not just gross reductions. In some cases, forfeiting high-value rebates may offset alternative funding gains. In other cases, operational complexity may create member disruption that affects adherence.
A data-driven evaluation ensures that projected savings translate into measurable results.
The Role of a Strategic TPA in Pharmacy Cost Management
Employers managing self-funded health plans need more than access to alternative funding programs. They need a strategic partner who understands how pharmacy benefits, rebates, PBM contracts, and member experience intersect.
At BRMS, pharmacy cost containment starts with claims-driven analysis. In partnership with Navion, we assess real plan data before implementing MAP, PAP, or CAP strategies.
Our approach includes:
- Reviewing historical claims and specialty utilization
- Evaluating rebate impact before implementation
- Ensuring PBM contract alignment
- Coordinating vendor relationships
- Monitoring performance and savings outcomes
- Supporting member communication to reduce disruption
Alternative funding programs are precision tools within a comprehensive pharmacy management strategy. They are most effective when implemented thoughtfully and monitored consistently.
Managing Specialty Pharmacy Costs in Self-Funded Health Plans
Employers need practical, sustainable solutions to manage specialty pharmacy spend without compromising member care.
MAPs, PAPs, and CAPs can be valuable components of a cost containment strategy. However, their success depends on strategic evaluation, contract alignment, and ongoing oversight.
Working with a TPA like BRMS, alongside pharmacy specialists such as Navion, ensures that alternative funding programs are implemented in away that:
- Increases net savings
- Protects rebate arrangements
- Maintains compliance
- Supports positive member experiences
With more than 30 years of serving self-funded employers, BRMS builds trusted and valued relationships and delivers strategies that work not just on paper, but in practice.